(Q37680018)

21 August 2017

1 reference

title

Management of behavioral problems in Alzheimer's disease (English)

1 reference

21 August 2017

0 references

Jeffrey Cummings

1 reference

21 August 2017

Henry Brodaty

1 reference

21 August 2017

Clive Ballard

1 reference

21 August 2017

Constantine G. Lyketsos

series ordinal

object named as

Constantine Lyketsos

1 reference

21 August 2017

George Grossberg

1 reference

21 August 2017

Serge Gauthier

1 reference

21 August 2017

Philippe Robert

series ordinal

1 reference

21 August 2017

publication date

25 January 2010

1 reference

International Psychogeriatrics

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

346-372

1 reference

Regression to the mean: implications for clinical trials of psychotropic agents in dementia

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Disruptive behavior as a predictor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Importance of lack of interest in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Behavioral Treatment of Depression in Dementia Patients: A Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Nonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The ICTUS Study: A Prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The utility of mandatory depression screening of dementia patients in nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Use of music to decrease aggressive behaviors in people with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Stage-specific prevalence of behavioral symptoms in Alzheimer's disease in a multi-ethnic community sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Predictors of nursing home admission for persons with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The cholinergic hypothesis of Alzheimer's disease: a review of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Animal-assisted therapy for dementia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Sexually inappropriate behaviour in demented elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The management of inappropriate vocalisation in dementia: a hierarchical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Development and validation of the Geriatric Anxiety Inventory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Management of agitation and aggression associated with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Epidemiology of apathy in older adults: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuroleptic drugs in dementia: benefits and harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Sleep disturbance in mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Syndromes of behavioural and psychological symptoms in mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Cholinergic deficits contribute to behavioral disturbance in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Design of Depression in Alzheimer's Disease Study-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Positron emission tomography metabolic correlates of apathy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuropathologic correlates of apathy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Reliability and validity of the apathy evaluation scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Premorbid personality and behavioral and psychological symptoms in probable Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Structural correlates of apathy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Need-driven dementia-compromised behavior: An alternative view of disruptive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Major depression in Alzheimer's disease. An interaction between gender and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Depression in Alzheimer's disease: overview and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Electroconvulsive therapy in a patient receiving rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Personality changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Bradycardia and hypotension in a patient with severe aortic stenosis receiving electroconvulsive therapy dose titration for treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Current treatments for sleep disturbances in individuals with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Development and validation of a geriatric depression screening scale: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Patient and caregiver characteristics and nursing home placement in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock".

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A pilot study of differences in behavioral and psychological symptoms of dementia in nursing home residents in Sydney and Shanghai

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The therapeutic design of environments for people with dementia: a review of the empirical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Behavioral effects of current Alzheimer's disease treatments: a descriptive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Old and ill and still feeling well? Determinants of subjective well-being in >or=60 year olds: the role of the sense of coherence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Clinical variables associated with psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Update on electroconvulsive therapy (ECT) in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Donepezil for the treatment of agitation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Frontal lobe hypometabolism and depression in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Clinical practice guidelines for severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Atypical antipsychotics and risk of cerebrovascular accidents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Functional neurochemistry of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Cognitive, affective, and behavioral effects of reminiscence group therapy on demented elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Behavioral Syndromes in Alzheimer’s Disease: Description and Correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Electroconvulsive therapy for agitation in Alzheimer disease: a case series

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Electroconvulsive therapy for the depressed elderly

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Double-blind trial of imipramine in Alzheimer's disease patients with and without depression

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Treatment of verbal agitation with a selective serotonin reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

The benefits and risks of ECT for patients with primary dementia who also suffer from depression

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Reality orientation and reminiscence therapy. A controlled cross-over study of elderly confused people

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Relationship of Family and Personal History to the Occurrence of Depression in Persons With Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Haloperidol for agitation in dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Necropsy evidence of central cholinergic deficits in senile dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Treatment of agitation and aggression in four demented patients using ECT

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Outcome of treatment of vocally disruptive behaviour in nursing home residents

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Withdrawal of Neuroleptic Medications from Institutionalized Dementia Patients: Results of a Double-Blind, Baseline-Treatment—Controlled Pilot Study

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Environmental "white noise": an intervention for verbally agitated nursing home residents

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Efficacy of psychosocial treatments for noisemaking in severe dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Effects of clinical supervision on nurse-patient cooperation quality: a controlled study in dementia care

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Project CARE: a randomized controlled trial of a behavioral intervention group for Alzheimer's disease caregivers

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Association between family history of affective disorder and the depressive syndrome of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Light Therapy for Managing Sleep, Behaviour, and Mood Disturbances in Dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Effects of individualized versus classical "relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Valproate preparations for agitation in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

Modeling caregiver adaptation over time: the longitudinal impact of behavior problems.

1 reference

https://api.crossref.org/works/10.1017%2FS1041610209991505

7 January 2021

10.1017/S1041610209991505

Identifiers

DOI

1 reference

21 August 2017

1 reference